Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
A loss of -1.200% shows a downward development for Hikma Pharmaceuticals.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -1.200% | 0.805% | 5.775% | -30.463% | -14.659% | -25.644% | -46.357% |
| Viatris Inc. | -1.220% | -1.373% | -4.963% | 73.146% | 9.065% | 26.472% | 2.097% |
| Opko Health Inc. | 3.740% | -0.330% | -1.889% | -21.692% | -14.236% | -27.933% | -73.232% |
| Amicus Therapeutics Inc. | -1.190% | 0.123% | -0.691% | 112.435% | 1.792% | 20.941% | 58.636% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat